Burnett Medical Center | |
257 W St George Ave, Grantsburg, Wisconsin 54840 | |
(715) 463-5355 | |
Name | Burnett Medical Center |
---|---|
Location | 257 W St George Ave, Grantsburg, Wisconsin |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 50 |
Occupancy Rate | 63.4% |
Medicare ID (CCN) | 525558 |
Legal Business Name | Burnett Medical Center Inc |
Ownership Type | Non Profit - Corporation |
NPI Number | 1487703815 |
Organization Name | BURNETT MEDICAL CENTER INC |
Address | 257 W Saint George Ave, Grantsburg, WI 54840 |
Phone Number | 715-463-5353 |
News Archive
Neurons, or nerve cells, in the brain communicate with each other by transmitting electric signals, or firing action potentials, through long processes named axons (which send out signals) and dendrites (which receive signals).
'Nanomaterials: Evolution and Advancement Towards Therapeutic Drug Delivery' gives the present status and future perspective of Polymeric nanoparticles, Liposomes, Carbon Nanotubes, Magnetic Nanoparticles, Silica Based nanomaterial, Hydrogels, Metallic Nanoparticles, Cyclodextrins, Poly (Lactide-Co-Glycolide) and its Copolymers.
'Some progress, but the big challenges remain'. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).
Deerfield Management Company, L.P.'s venture capital fund, Deerfield Healthcare Innovations Fund, L.P., today announced its first therapeutics-based investment by participating, along with Deerfield Private Design Fund III, in providing financing to Editas Medicine. In total, Deerfield invested $20 million in this early-stage institutional financing.
US HIFU, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today its exclusive partnership with Riverside Research Institute (RRI) to develop and test an ultrasonic method of prostate imaging and treatment that combines advanced tissue-type imaging with ultrasound energy from the Sonablate® 500 medical device.
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Neurons, or nerve cells, in the brain communicate with each other by transmitting electric signals, or firing action potentials, through long processes named axons (which send out signals) and dendrites (which receive signals).
'Nanomaterials: Evolution and Advancement Towards Therapeutic Drug Delivery' gives the present status and future perspective of Polymeric nanoparticles, Liposomes, Carbon Nanotubes, Magnetic Nanoparticles, Silica Based nanomaterial, Hydrogels, Metallic Nanoparticles, Cyclodextrins, Poly (Lactide-Co-Glycolide) and its Copolymers.
'Some progress, but the big challenges remain'. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).
Deerfield Management Company, L.P.'s venture capital fund, Deerfield Healthcare Innovations Fund, L.P., today announced its first therapeutics-based investment by participating, along with Deerfield Private Design Fund III, in providing financing to Editas Medicine. In total, Deerfield invested $20 million in this early-stage institutional financing.
US HIFU, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today its exclusive partnership with Riverside Research Institute (RRI) to develop and test an ultrasonic method of prostate imaging and treatment that combines advanced tissue-type imaging with ultrasound energy from the Sonablate® 500 medical device.
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 15.15 | 14.46 |
Percentage of long-stay residents who lose too much weight | 3.76 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44.16 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 7.53 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 1.99 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 7.43 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.59 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 25.12 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 4.51 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 3.53 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.8 | 95.98 |